Jun. 19, 2012
June 20, 2012. Xiamen Innovax Biotech expects to launch Hecolin, its hepatitis E vaccine, in China later this year. It will form partnerships to bring the product to worldwide markets. In January of this year, the SFDA approved the vaccine after it was effective in a large Phase III trial whose results were published in the medical journal The Lancet in 2010. The trial found the drug to be 100 per cent effective in preventing infection.
Innovax is the development arm of the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University.